Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Kedudukan dalam Saham #13173
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Harga Saham
$8.46
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$514.33M
Perubahan (1 hari)
-2.08%
Perubahan (1 tahun)
128.03%
Negara
US
Perdagangan Kyverna Therapeutics, Inc. (KYTX)

Kategori

Sejarah hasil dividen untuk Kyverna Therapeutics, Inc. (KYTX)
Hasil dividen (TTM) bagi Kyverna Therapeutics, Inc. (simbol saham: KYTX) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Kyverna Therapeutics, Inc. (KYTX) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH